Safety and Efficacy of Biodegradable Polymer-Coated Sirolimus-Eluting Stents in "Real-World" Practice 18-Month Clinical and 9-Month Angiographic Outcomes

被引:71
作者
Han, Yaling [1 ]
Jing, Quanmin [1 ]
Xu, Bo [2 ,3 ]
Yang, Lixia [4 ]
Liu, Huiliang [5 ]
Shang, Xiaoming [6 ]
Jiang, Tieming [7 ]
Li, Zhanquan [8 ]
Zhang, Hua [9 ]
Li, Hui [10 ]
Qiu, Jian [11 ]
Liu, Yingfeng [12 ]
Li, Yi [1 ]
Chen, Xuezhi [1 ]
Gao, Runlin [2 ,3 ]
机构
[1] Shenyang No Hosp, Dept Cardiol, Shenyang 110016, Peoples R China
[2] Cardiovasc Inst, Beijing, Peoples R China
[3] Fuwai Hosp, Beijing, Peoples R China
[4] Kunming Gen Hosp Chengdu Mil Reg, Kunming, Peoples R China
[5] Gen Hosp Armed Police Forces, Beijing, Peoples R China
[6] Tangshan Gongren Hosp, Tangshan, Peoples R China
[7] Affiliated Hosp, Chinese Peoples Armed Police Forces Med Coll, Tianjin, Peoples R China
[8] Peoples Hosp Liaoning Prov, Shenyang, Peoples R China
[9] Shanxi Prov Corps Hosp Chinese Peoples Armed Poli, Xian, Peoples R China
[10] Daqing Oilfields Gen Hosp, Daqing, Peoples R China
[11] Guangzhou Army Gen Hosp, Guangzhou, Guangdong, Peoples R China
[12] So Med Univ, Zhujiang Hosp, Guangzhou, Guangdong, Peoples R China
关键词
drug-eluting stents; sirolimus; biodegradable polymer; coronary heart disease; CORONARY-THROMBOSIS; IMPLANTATION; LESIONS; TRIALS; HYPERSENSITIVITY; DISCONTINUATION; CARDIOLOGY; ARTERIES; EVENTS;
D O I
10.1016/j.jcin.2008.12.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives This study sought to evaluate the safety and efficacy of a biodegradable polymer-coated sirolimus-eluting stent (Excel, JW Medical System, Weihai, China) with 6-month dual antiplatelet therapy in daily practice. Background It has been hypothesized that persistent presence of polymer may compromise the safety of drug-eluting stents, and that therefore biodegradable polymer coatings might reduce late adverse events. Methods Between June and November 2006, 2,077 patients, exclusively treated with Excel stents at 59 centers from 4 countries, were enrolled in this prospective, multicenter registry. Recommended antiplatelet regimen included clopidogrel and aspirin for 6 months followed by chronic aspirin therapy. Results The average duration of clopidogrel treatment was 199.8 +/- 52.7 days and 80.5% of discharged patients discontinued clopidogrel at 6 months. The cumulative rates of major adverse cardiac events were 0.9% at 30 days, 2.7% at 1 year, and 3.1% at 18 months. Overall rate of stent thrombosis was 0.87% at 18 months. The rates of acute, subacute, late, and very late stent thrombosis were 0.1%, 0.38%, 0.34%, and 0.05%, respectively. Angiographic follow-up, performed in 974 (31.6%) lesions from 653 patients (31.7%), revealed a mean in-stent late lumen loss of 0.21 +/- 0.39 mm. Binary restenosis rates were 3.8% in-stent and 6.7% in-segment. Conclusions This multicenter registry documents satisfactory safety and efficacy profiles, as evidenced by low rates of major adverse cardiac events and stent thrombosis up to 18 months, for the Excel biodegradable polymer-based sirolimus-eluting stent when used with 6 months of dual antiplatelet therapy in a "real-world" setting. (Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent [CREATE]; NCT00331578) (J Am Coll Cardiol Intv 2009;2:303-9) (C) 2009 by the American College of Cardiology Foundation
引用
收藏
页码:303 / 309
页数:7
相关论文
共 36 条
[1]   A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents [J].
Babapulle, MN ;
Joseph, L ;
Bélisle, P ;
Brophy, JM ;
Eisenberg, MJ .
LANCET, 2004, 364 (9434) :583-591
[2]   Novel paclitaxel-eluting, biodegradable polyrmer coated stent in the treatment of de novo coronary lesions:: A prospective multicenter registry [J].
Buszman, Pawel ;
Trznadel, Stanislaw ;
Milewski, Krzysztof ;
Rzezniczak, Janusz ;
Przewlocki, Tadeusz ;
Kosmider, Maciej ;
Wojcik, Jaroslaw ;
Janczak, Jacek ;
Zurakowski, Aleksander ;
Kondys, Marek ;
Krol, Marek ;
Kinasz, Leszek ;
Jaklik, Andrzej ;
Rzeszutko, Lukasz ;
Kaluza, Grzegorz L. ;
Kiesz, Stephan ;
Gil, Robert .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2008, 71 (01) :51-57
[3]  
Commandeur Suzan, 2006, J Interv Cardiol, V19, P500, DOI 10.1111/j.1540-8183.2006.00198.x
[4]   Clinical end points in coronary stent trials - A case for standardized definitions [J].
Cutlip, Donald E. ;
Windecker, Stephan ;
Mehran, Roxana ;
Boam, Ashley ;
Cohen, David J. ;
van Es, Gerrit-Anne ;
Steg, P. Gabriel ;
Morel, Marie-angele ;
Mauri, Laura ;
Vranckx, Pascal ;
McFadden, Eugene ;
Lansky, Alexandra ;
Hamon, Martial ;
Krucoff, Mitchell W. ;
Serruys, Patrick W. .
CIRCULATION, 2007, 115 (17) :2344-2351
[5]   Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice:: data from a large two-institutional cohort study [J].
Daemen, Joost ;
Wenaweser, Peter ;
Tsuchida, Keiichi ;
Abrecht, Linda ;
Sophia, Vaina ;
Morger, Cyrill ;
Kukreja, Neville ;
Jueni, Peter ;
Sianos, Georgios ;
Hellige, Gerrit ;
van Domburg, Ron T. ;
Hess, Otto M. ;
Boersma, Eric ;
Meier, Bernhard ;
Windecker, Stephan ;
Serruys, Patrick W. .
LANCET, 2007, 369 (9562) :667-678
[6]   Vascular responses to drug eluting stents - Importance of delayed healing [J].
Finn, Aloke V. ;
Nakazawa, Gaku ;
Joner, Michael ;
Kolodgie, Frank D. ;
Mont, Erik K. ;
Gold, Herman K. ;
Virmani, Renu .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (07) :1500-1510
[7]   Safety and efficacy of the CYPHER Select Sirolimus-eluting stent in the "real world" - Clinical and angiographic results from the China CYPHER select registry [J].
Gao, Run-lin ;
Xu, Bo ;
Lu, Shu-zheng ;
Chen, Ji-lin ;
Han, Ya-ling ;
Chen, Jun-zhu ;
Gai, Lu-yue ;
Ge, Jun-bo ;
Wang, Wei-min ;
Du, Zhi-min ;
Huo, Yong ;
Wang, Le-feng ;
Gao, Wei ;
Chen, Ji-yan ;
He, Ben ;
Jia, Guo-liang ;
Yang, Zhi-jian ;
Cao, Ke-jiang ;
Li, Wei-min ;
Shen, Wei-feng ;
Wan, Zheng ;
Huang, De-jia ;
Zhu, Guo-ying .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2008, 125 (03) :339-346
[8]   Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries [J].
Ge, Junbo ;
Qian, Juying ;
Wang, Xiangfei ;
Wang, Qibing ;
Yan, Wei ;
Yan, Yan ;
Fan, Bing ;
Ge, Lei ;
Liu, Xuebo .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2007, 69 (02) :198-202
[9]   Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents - A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians [J].
Grines, Cindy L. ;
Bonow, Robert O. ;
Casey, Donald E., Jr. ;
Gardner, Timothy J. ;
Lockhart, Peter B. ;
Moliterno, David J. ;
O'Gara, Patrick ;
Whitlow, Patrick .
CIRCULATION, 2007, 115 (06) :813-818
[10]   Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer [J].
Grube, E ;
Sonoda, S ;
Ikeno, F ;
Honda, Y ;
Kar, S ;
Chan, C ;
Gerckens, U ;
Lansky, AJ ;
Fitzgerald, PJ .
CIRCULATION, 2004, 109 (18) :2168-2171